WO1997028812A2 - Pharmaceutical compositions for biological treatment of infections by enterococcus faecium strains resistant to antibiotics and to vancomycin in particular (vre) - Google Patents
Pharmaceutical compositions for biological treatment of infections by enterococcus faecium strains resistant to antibiotics and to vancomycin in particular (vre) Download PDFInfo
- Publication number
- WO1997028812A2 WO1997028812A2 PCT/EP1997/000558 EP9700558W WO9728812A2 WO 1997028812 A2 WO1997028812 A2 WO 1997028812A2 EP 9700558 W EP9700558 W EP 9700558W WO 9728812 A2 WO9728812 A2 WO 9728812A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- enterococcus faecium
- strain
- vancomycin
- infections
- vre
- Prior art date
Links
- 241000194031 Enterococcus faecium Species 0.000 title claims abstract description 45
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 108010059993 Vancomycin Proteins 0.000 title claims abstract description 17
- 229960003165 vancomycin Drugs 0.000 title claims abstract description 17
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 title claims abstract description 17
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 7
- 229940088710 antibiotic agent Drugs 0.000 title claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 4
- 229940126601 medicinal product Drugs 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 9
- 206010022678 Intestinal infections Diseases 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 238000010926 purge Methods 0.000 claims description 2
- 238000009792 diffusion process Methods 0.000 claims 1
- 230000008029 eradication Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108010062877 Bacteriocins Proteins 0.000 description 4
- 206010011409 Cross infection Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000000369 enteropathogenic effect Effects 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000589876 Campylobacter Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 241000589989 Helicobacter Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
Definitions
- said patent relates to compositions in which bacteria of Enterococcus faecium species are used which belong to SF68 bacterial strain.
- SF68 bacterial strain is the active principle of the patent medicine BIOFLORIN®, a well-documented biological preparation containing this particular strain of Enterococcus faecium in dry form, widely used for treating acute diarrhoeal enterocolitis forms.
- Enterococcus faecium formerly classified within the family of Streptococcacee, Streptococcus genus of Lancefield' s D group, has been considered as belonging to Enterococcus genus, and appears as being a gram +, aerobic, facultative anaerobic, non-sporigenous, non-mobile spherical coccus of approximately 1 ⁇ of diameter, generally forming variously long chains of cells.
- the optimal growth temperature is of 36-37°C, and the optimal growth pH value is 7.
- the particularly suitable culture media for an optimal growth are MRS broth (Difco) and horse blood agar.
- the growth can be estimated from a uniform turbidity in liquid media and the formation of small round, slightly convex, smooth colonies on solid media. On colonies growing in blood agar a slight ⁇ -hemolysis can be observed.
- SF68 strain was originally isolated from human organisms and was also used in food industry, in particular for cheese fermentation.
- Giuliani Company developed their preparation during 1978-1980, through a very large amount of toxicological, microbiological and clinical studies; nearly all of the latter were carried out as controlled double-blind vs. placebo or vs. active control studies.
- the survey by Loizeau E. (published on "Revue Medicale de la Canal Ro ande” 114; 651, 1994) summarizes the biological and clinical properties of the preparation.
- VRE vancomycin-resistant enterococci because they are very often implied in nosocomial emergencies (nosocomial or hospital infections) with a high potential of morbility and mortality, as observed from important epidemiological studies performed in the U.S.A. and Europe.
- Campylobacter whereas rather low resulted to be the activity against Helicobacter pilori.
- Enterococcus faecium shows the capability of regularly inhibiting, by means of the production of biologically active substances, with a reproducibility of 100%, the growth of other vancomycin-resistant (VRE) strains of Enterococcus faecium of Van-A and Van-B types, against which it was tested.
- VRE vancomycin-resistant
- the microbiological studies were carried out according to the proper microbiologic methods.
- the cultivation of Enterococcus faecium strains was carried out in Mueller-Hinton II broth, overnight at 37°C under a 5% C0 2 atmosphere.
- the culture of bacteriocins producer SF68 strain was centrifuged at 13,000 rpm during 5 minutes in order to remove the cells, and the cell-free supernatant was then incubated at 80°C during 1 minute (most bacteriocins survive this treatment which allows the operators to prevent producer cells from further growing) .
- the observations at time points "0", "4", "8" and "30" hours were carried out on microtitration plates, to which the following media had been added:
- the strains of Enterococcus faecium showing charactetistics of resistance to vancomycin (either of Van-A or Van-B type) against which the antibacterial activity of Enterococcus faecium SF68 strain was tested had been isolated in human clinic from different sources (comprising faeces, blood, infected wounds) on the occasion of a multicentric epidemiological study carried out in Belgium.
- the "Van" genotype was determined by using a "PCR” based on the technique described by Dutka-Malen et al. ("Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci” - J. Clin. Microbiol. 33: 24- 27 - 1995) .
- Other strains of Enterococcus faecium came from collections (LGM — see following table) .
- Van-B type 1 1 100 %
- VRE's vancomycin-resistant enterococci
- the subjects were treated with a pharmaceutical preparation in the form of capsules containing at least 75 x 10 6 CFU of Enterococcus faecium SF68® strain per each capsule (available under the trade name BIOFLORIN®) , administered at the dosage of 2 capsules three times per day during 5 days.
- the control coprocultures were performed at time "0", then after the 5 treatment days and were then repeated after 1, 3, 5, and 25 days from treatment end.
- the strains of Enterococcus faecium must display vital characteristics and the CFU ("colony forming unit") amount to be administered every day must range from 10,000,000 units up to more than 10,000,000,000 units; the width of the dosage range is justified by the matter of fact that the essential aspect for the biological effect is that conditions exist in the body which allow the bacteria to multiply — which, per se, typically multiply very rapidly (doubling in number every 19 minutes) .
- CFU colony forming unit
- compositions the following examples may be cited: 1) Hard gelatine capsules Per each capsule: - Enterococcus faecium SF68 strain >75,000,000
- the pellets can be made gastroresistant by coating them with a shell of methacrylic acid polymers.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96MI000239A IT1282586B1 (it) | 1996-02-08 | 1996-02-08 | Composizioni farmaceutiche per il trattamento biologico delle infezioni dovute a ceppi di enterococcus faecium resistenti agli |
| ITMI96A000239 | 1996-02-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997028812A2 true WO1997028812A2 (en) | 1997-08-14 |
| WO1997028812A3 WO1997028812A3 (en) | 1997-10-02 |
Family
ID=11373201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1997/000558 WO1997028812A2 (en) | 1996-02-08 | 1997-02-05 | Pharmaceutical compositions for biological treatment of infections by enterococcus faecium strains resistant to antibiotics and to vancomycin in particular (vre) |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | IT1282586B1 (enrdf_load_stackoverflow) |
| WO (1) | WO1997028812A2 (enrdf_load_stackoverflow) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303312B1 (en) | 1996-07-31 | 2001-10-16 | California Institute Of Technology | Complex formation between dsDNA and oligomer of cyclic heterocycles |
| US6392012B1 (en) | 1998-12-23 | 2002-05-21 | Advanced Medicine, Inc. | Glycopeptide derivatives and pharmaceutical compositions containing the same |
| US6472537B1 (en) | 1996-02-26 | 2002-10-29 | California Institute Of Technology | Polyamides for binding in the minor groove of double stranded DNA |
| US6518242B1 (en) | 1998-02-20 | 2003-02-11 | Theravance, Inc. | Derivatives of glycopeptide antibacterial agents |
| EP1477555A3 (en) * | 2003-05-15 | 2004-12-15 | Yasuo Kawai | Method for culturing bacterial cells belonging to the enterococcus genus and method of producing killed bacterial cells belonging to the enterococcus genus |
| WO2005018654A1 (fr) * | 2003-08-26 | 2005-03-03 | Obschestvo S Ogranichennoi Otvetstvennostyu Alef-Farma | Utilisation de souches de enterococcus faecium pour traiter l'insuffisance hepatique, pour regenerer et pour intensifier le metabolisme hepatique |
| WO2007035938A2 (en) | 2005-09-22 | 2007-03-29 | Medivas, Llc | BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE |
| WO2007038246A2 (en) | 2005-09-22 | 2007-04-05 | Medivas, Llc | Solid polymer delivery compositions and methods for use thereof |
| EP1852122A1 (en) * | 2006-05-02 | 2007-11-07 | Truffini & Regge' Farmaceutici SRL | Dental and gingival health compositions containing reactivatable, dehydrated, eubiotic micro-organisms |
| WO2009081958A1 (ja) | 2007-12-26 | 2009-07-02 | Shionogi & Co., Ltd. | グリコペプチド抗生物質配糖化誘導体 |
| WO2009123713A1 (en) | 2008-04-01 | 2009-10-08 | Cornell University | Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof |
| EP2164333A4 (en) * | 2007-05-24 | 2010-07-28 | Nestec Sa | COMPOSITIONS AND METHODS USEFUL FOR MODULATING IMMUNITY, IMPROVING THE EFFICACY OF A VACCINE, REDUCING THE MORBIDITY ASSOCIATED WITH CHRONIC INFECTIONS BY FHV-1, AND PREVENTING OR TREATING CONJUNCTIVITIS |
| EP2314599A1 (en) | 2004-11-29 | 2011-04-27 | National University Corporation Nagoya University | Glycopeptide antibiotic monomer derivatives |
| IT202200013138A1 (it) * | 2022-06-22 | 2023-12-22 | Cerbios Pharma Sa | Probiotico per l’uso nel trattamento di alterazioni infiammatorie della mucosa intestinale, in particolare obesità |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1112479B (it) * | 1979-04-02 | 1986-01-13 | Giuliani Sa | Composizione farmaceutica particolarmente atta alla terapia di enteriti e di affezioni diarroiche generiche |
| EP0405569A1 (de) * | 1989-06-30 | 1991-01-02 | Cernitin S.A. | Produkt mit antimikrobieller Wirksamkeit, Verfahren zu dessen Isolierung aus dem Kulturmedium von Streptokokkus faecium und pharmazeutisches Präparat, enthaltend dieses Produkt mit antimikrobieller Wirksamkeit |
-
1996
- 1996-02-08 IT IT96MI000239A patent/IT1282586B1/it active IP Right Grant
-
1997
- 1997-02-05 WO PCT/EP1997/000558 patent/WO1997028812A2/en active Application Filing
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6472537B1 (en) | 1996-02-26 | 2002-10-29 | California Institute Of Technology | Polyamides for binding in the minor groove of double stranded DNA |
| US6303312B1 (en) | 1996-07-31 | 2001-10-16 | California Institute Of Technology | Complex formation between dsDNA and oligomer of cyclic heterocycles |
| US6518242B1 (en) | 1998-02-20 | 2003-02-11 | Theravance, Inc. | Derivatives of glycopeptide antibacterial agents |
| US7101964B2 (en) | 1998-12-23 | 2006-09-05 | Theravance, Inc. | Intermediate for preparing glycopeptide derivatives |
| US6455669B1 (en) | 1998-12-23 | 2002-09-24 | Theravance, Inc. | Glycopeptide derivatives and pharmaceutical compositions containing the same |
| US6444786B1 (en) | 1998-12-23 | 2002-09-03 | Advanced Medicine, Inc. | Glycopeptide derivatives and pharmaceutical compositions containing the same |
| US6962970B2 (en) | 1998-12-23 | 2005-11-08 | Theravance, Inc. | Glycopeptide derivatives and pharmaceutical compositions containing the same |
| US7723470B2 (en) | 1998-12-23 | 2010-05-25 | Theravance, Inc. | Glycopeptide derivatives and pharmaceutical compositions containing the same |
| US6392012B1 (en) | 1998-12-23 | 2002-05-21 | Advanced Medicine, Inc. | Glycopeptide derivatives and pharmaceutical compositions containing the same |
| US7351791B2 (en) | 1998-12-23 | 2008-04-01 | Theravance, Inc. | Intermediate for preparing glycopeptide derivatives |
| EP1477555A3 (en) * | 2003-05-15 | 2004-12-15 | Yasuo Kawai | Method for culturing bacterial cells belonging to the enterococcus genus and method of producing killed bacterial cells belonging to the enterococcus genus |
| WO2005018654A1 (fr) * | 2003-08-26 | 2005-03-03 | Obschestvo S Ogranichennoi Otvetstvennostyu Alef-Farma | Utilisation de souches de enterococcus faecium pour traiter l'insuffisance hepatique, pour regenerer et pour intensifier le metabolisme hepatique |
| US8778874B2 (en) | 2004-11-29 | 2014-07-15 | National University Corporation Nagoya University | Glycopeptide antibiotic monomer derivatives |
| EP2314599A1 (en) | 2004-11-29 | 2011-04-27 | National University Corporation Nagoya University | Glycopeptide antibiotic monomer derivatives |
| WO2007035938A2 (en) | 2005-09-22 | 2007-03-29 | Medivas, Llc | BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE |
| WO2007038246A2 (en) | 2005-09-22 | 2007-04-05 | Medivas, Llc | Solid polymer delivery compositions and methods for use thereof |
| EP1852122A1 (en) * | 2006-05-02 | 2007-11-07 | Truffini & Regge' Farmaceutici SRL | Dental and gingival health compositions containing reactivatable, dehydrated, eubiotic micro-organisms |
| EP2164333A4 (en) * | 2007-05-24 | 2010-07-28 | Nestec Sa | COMPOSITIONS AND METHODS USEFUL FOR MODULATING IMMUNITY, IMPROVING THE EFFICACY OF A VACCINE, REDUCING THE MORBIDITY ASSOCIATED WITH CHRONIC INFECTIONS BY FHV-1, AND PREVENTING OR TREATING CONJUNCTIVITIS |
| WO2009081958A1 (ja) | 2007-12-26 | 2009-07-02 | Shionogi & Co., Ltd. | グリコペプチド抗生物質配糖化誘導体 |
| US8481696B2 (en) | 2007-12-26 | 2013-07-09 | Shionogi & Co., Ltd. | Glycosylated glycopeptide antibiotic derivatives |
| WO2009123713A1 (en) | 2008-04-01 | 2009-10-08 | Cornell University | Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof |
| IT202200013138A1 (it) * | 2022-06-22 | 2023-12-22 | Cerbios Pharma Sa | Probiotico per l’uso nel trattamento di alterazioni infiammatorie della mucosa intestinale, in particolare obesità |
| WO2023247472A1 (en) * | 2022-06-22 | 2023-12-28 | Cerbios-Pharma Sa | Probiotic for use in the treatment of inflammatory alterations of the intestinal mucosa, particularly obesity |
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI960239A0 (enrdf_load_stackoverflow) | 1996-02-08 |
| IT1282586B1 (it) | 1998-03-31 |
| ITMI960239A1 (it) | 1997-08-08 |
| WO1997028812A3 (en) | 1997-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rosander et al. | Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938 | |
| Privitera et al. | Transfer of multiple antibiotic resistance between subspecies of Bacteroides fragilis | |
| EP0760848B1 (en) | Lactobacillus strains of human origin, their compositions and uses thereof | |
| US6849256B1 (en) | Inhibition of pathogens by probiotic bacteria | |
| KR20200136365A (ko) | 공동선택 미생물총을 포함하는 조성물 및 그 이용 방법 | |
| Naderi et al. | Study of antagonistic effects of Lactobacillus strains as probiotics on multi drug resistant (MDR) bacteria isolated from urinary tract infections (UTIs) | |
| US20110236359A1 (en) | Antimicrobial Activity of Bacteriocin-Producing Lactic Acid Bacteria | |
| US11458177B2 (en) | Enterococcus faecium bacteriophage Ent-FAP-4 and use for inhibiting Enterococcus faecium proliferation of same | |
| WO1997028812A2 (en) | Pharmaceutical compositions for biological treatment of infections by enterococcus faecium strains resistant to antibiotics and to vancomycin in particular (vre) | |
| US11412760B2 (en) | Escherichia coli bacteriophage Esc-COP-7, and use thereof for suppressing proliferation of pathogenic Escherichia coli | |
| US11457635B2 (en) | Pseudomonas aeruginosa bacteriophage Pse-AEP-3 and use thereof for inhibiting proliferation of Pseudomonas aeruginosa | |
| US11497216B2 (en) | Pseudomonas aeruginosa bacteriophage pse-AEP-4 and use thereof for inhibiting proliferation of Pseudomonas aeruginosa | |
| KR101966772B1 (ko) | 락토바실러스 루테리 cs 132(kctc 11452bp) 또는 이의 배양물을 포함하는 구강병원균 억제조성물 | |
| CN113166730B (zh) | 新型猪链球菌噬菌体str-sup-1及其在抑制猪链球菌细菌增殖方面的用途 | |
| KR100736517B1 (ko) | 장내 유해세균 억제능을 갖는 락토바실루스 존소니이 아이디씨씨 9203 | |
| US11213050B2 (en) | Escherichia coli bacteriophage Esc-COP-9 and use for inhibiting proliferation of pathogenic Escherichia coli thereof | |
| US11701398B2 (en) | Compositions and methods for inhibiting the proliferation of pathogenic Escherichia coli | |
| US11596659B2 (en) | Compositions and methods for inhibiting the proliferation of pathogenic Escherichia coli | |
| Miranda et al. | Endocarditis caused by nonhemolytic group B streptococcus | |
| US11583565B2 (en) | Compositions and methods for inhibiting the proliferation of pathogenic Escherichia coli | |
| US20240366695A1 (en) | Compositions and methods for inhibiting the proliferation of pathogenic escherichia coli | |
| Chepchumba et al. | Isolation of phages against Streptococcus species in the oral cavity for potential control of dental diseases and associated systemic complications | |
| Ngu | Genotypic and Phenotypic characterization of enterococci from cow dung and environmental water sources in three selected dairy farms in Amathole District |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97528161 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |